Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Signaturefd LLC

Signaturefd LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,126 shares of the biopharmaceutical company’s stock after buying an additional 54 shares during the quarter. Signaturefd LLC’s holdings in Regeneron Pharmaceuticals were worth $1,867,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $697,296,000. FMR LLC increased its stake in Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the last quarter. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares during the last quarter. Moneta Group Investment Advisors LLC increased its stake in Regeneron Pharmaceuticals by 57,848.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after acquiring an additional 581,379 shares during the last quarter. Finally, abrdn plc increased its stake in Regeneron Pharmaceuticals by 552.8% during the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after acquiring an additional 186,215 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.3 %

REGN traded up $2.83 on Friday, reaching $896.82. The company’s stock had a trading volume of 507,466 shares, compared to its average volume of 412,356. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The business’s 50 day moving average is $953.01 and its 200 day moving average is $891.67. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The stock has a market cap of $98.43 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter last year, the business posted $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Finally, Truist Financial reiterated a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $976.41.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the sale, the director now owns 1,382 shares in the company, valued at $1,353,323.50. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock valued at $13,124,641 in the last quarter. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.